参考文献/References:
[1]Brookmeyer R,Johnson E,Ziegler-Graham K,et al.Forecasting the globalburden of Alzheimer's disease[J].Alzheimer's and Dementia,2007,3(3):186-191.
[2]王鸿飞,安丽.阿尔茨海默病的发病机制及营养调节[J].国际老年医学杂志,2010,31(5):230-234.
[3]Wenk G L.Neuropathologic changes in Alzheimer's disease[J].J Clin Psychiatry,2003,64(9):7-10.
[4]Ghezzi L,Scarpini E,Galimberti D.Disease-modifying drugs in Alzheimer's disease[J].Drug Des Devel Ther,2013,7:1471-1478.
[5]Galimberti D,Scarpini E.Disease-modifying treatments for Alzheimer's disease[J].Adv Neurol Disord,2011,4(4):203-216.
[6]Mahley R W,Weisgraber K H,Huang Y.Apolipoprotein E4:A causative factor andtherapeutic target in neuropathology,including Alzheimer's disease[J].ProcNatl Acad Sc USA,2006,103(15):5644-5651.
[7]Francis P T,Palmer A M,Snape M,et al.The cholinergic hypothesis of Alzheimer's disease:a review of progress[J].J Neurol Neurosurg Psychiatr,1999,66(2):137-147.
[8]Hardy J,Allsop D.Amyloid deposition as the central event in the aetiology of Alzheimer's disease[J].Trends Pharmacol Sci,1991,12(10):383-388.
[9]Nikolaev A,McLaughlin T,O'Leary D,et al.APP binds DR6 to cause axon pruning and neuron death via distinct caspases[J].Nature,2009,457:981-989.
[10]Hernández F,Avila J.Tauopathies[J].Cell Mol Life Sci,2007,64(17):2219-2233.
[11]Mudher A,Lovestone S.Alzheimer's disease-do tauists and baptists finally shake hands?[J].Trends Neurosci,
2002,25(1):22-26.
[12]Holmes C,Boche D,Wilkinson D,et al.Long-term effects of Abeta42 immunization in Alzheimer's disease:follow-up of a randomised,placebo-controlled phase Ⅰ trial[J].
Lancet,2008,372:216-223.
[13]Bartzokis G.Alzheimer's disease as homeostatic responses to age-related myelin breakdown[J].Neurobiol Aging,2011,32(8):1341-1371.
[14]Lott I T,Head E.Alzheimer disease and Down syndrome:factors in pathogenesis[J].Neurobiol Aging,2005,26(3):383-389.
[15]Su B,Wang X,Nunomura A,et al.Oxidative stress signaling in Alzheimer's disease[J].Curr Alzheimer Res,2008,5(6):525-532.
[16]Singh I,Sagare A P,Coma M,et al.Low levels of copper disrupt brain amyloid-beta homeostasis by altering its production and clearance[J].Proc Natl AcadSci USA,2013,110:14771-14776.
[17]Pohanka M.Acetylcholinesterase inhibitors; a patent review(2008-present)[J].Expert Opinion on Therapeutic Patents,2012,22(8):871-886.
[18]Colovic M B,Krstic D Z,Lazarevic-Pasti T D,et al.Acetylcholinesteraseinhibitors:Pharmacology and toxicology[J].Current Neuropharmacology,2013,11(3):315-335.
[19]Chen H S,Lipton S A.The chemical biology of clinically tolerated NMDA receptor antagonists[J].Journal of Neurochemistry,2006,97(6):1611-1626.
[20]Szekely C,Thorne J,Zandi P,et al.Nonsteroidal anti-inflammatory drugs forthe prevention of Alzheimer's disease:a systematic review[J].Neuroepidemiology,2004,23:159-169.
[21]Gilgun-Sherki Y,Melamed E,Offen D.Antioxidant treatment in Alzheimer's disease[J].J Mol Neurosci,2003,21(1):1-11.
[22]Bliwise D B.Sleep apnea, APOE4 and Alzheimer's disease 20 yearsand counting[J].J Psychosomatic Res,2002,53(1):539-546.
[23]Gelinas D S,DaSilva K,Fenili D,et al.Immunotherapy for Alzheimer's disease[J].Proc Natl Acad Sci USA,2004,101:14657-14662.
[24]Morgan D.Immunotherapy for Alzheimer's disease[J].J Intern Med,2011,269(1):54-63.
[25]Cuajungco M P,Frederickson C J,Bush A I.Amyloid-beta metal interaction and metal chelation[J].Subcell Biochem,2005,38:235-254.
[26]Ryan J M,Grundman M.Anti-amyloid-beta immunotherapy in Alzheimer's disease:ACC-001 clinical trials are ongoing[J].J Alzheimers Dis,2009,17(2):243.
[27]Blennow K,Zetterberg H,Rinne J O,et al.Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderateAlzheimer disease[J].Arch Neurol,2012,69(8):1002-1010.
[28]Portelius E,Price E,Brinkmalm G,et al.A novel pathway for amyloid precursor protein processing[J].Neurobiol Aging,2011,32(6):1090-1098.
[29]Turner P R,O'Connor K,Tate W P,et al.Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory[J].Progress in Neurobiology,2003,70(1):1-32.
[30]Bosco D,Fava A,Plastino M,et al.Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis[J].J Cellular Mol Med,2011,15(9):1807-1821.
[31]Han W,Li C.Linking type 2 diabetes and Alzheimer's disease[J].Proc Natl Acad Sci USA,2010,107:6557-6558.
[32]Bajda M,Guzior N,Ignasik M,et al.Multi-target-directed ligands in Alzheimer's disease treatment[J].Curr Med Chem,2011,18(32):4949-4975.